Hillstream Biopharma (NASDAQ:CNTN) Stock Rating Lowered by Wall Street Zen

Hillstream Biopharma (NASDAQ:CNTN) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Sunday.

Separately, Weiss Ratings upgraded Hillstream Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Hillstream Biopharma Stock Up 3.9%

Hillstream Biopharma stock traded up $0.09 during mid-day trading on Friday, reaching $2.38. 641,379 shares of the stock traded hands, compared to its average volume of 1,261,309. The firm has a market capitalization of $183.55 million, a PE ratio of -2.07 and a beta of 1.42. Hillstream Biopharma has a 12-month low of $1.08 and a 12-month high of $9.08. The firm’s 50-day simple moving average is $3.01.

Insiders Place Their Bets

In other Hillstream Biopharma news, Director Gary S. Stetz sold 87,851 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $3.42, for a total transaction of $300,450.42. Following the completion of the sale, the director owned 146,675 shares of the company’s stock, valued at approximately $501,628.50. The trade was a 37.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 3.34% of the company’s stock.

About Hillstream Biopharma

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.